Acurx Pharmaceuticals Inc. $(ACXP)$, a late-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company posted a net loss of $2.2 million for the three months ended June 30, 2025, compared to a net loss of $4.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $4.4 million, a decrease from the net loss of $8.5 million reported for the same period in 2024. The company successfully executed a warrant inducement transaction, resulting in gross proceeds of approximately $2.7 million, with net proceeds of $2.5 million after deducting fees and transaction expenses. Acurx Pharmaceuticals continues its multi-step approach to raising capital through various financings, warrant inducements, and public-private partnership opportunities. In June, significant progress was made with the publication of Phase 2b clinical trial data for ibezapolstat in C. Difficile infection in the Lancet Microbe, a leading microbiology research journal.